Cas:146916-90-7 2,3-Dichloro-1,1,1,3-tetrafluoropropane manufacturer & supplier

Chemical Name:2,3-Dichloro-1,1,1,3-tetrafluoropropane

CAS.NO:146916-90-7

Synonyms:2,3-dichloro-1,1,1,3-tetrafluoropropane

Molecular Formula:C₃H₂Cl₂F₄

Molecular Weight:184.94800

HS Code:

Physical and Chemical Properties:

Melting point:-98ºC

Boiling point:70ºC

Density:1.498g/cm3

Index of Refraction:1.344

PSA:

Exact Mass:183.94700

LogP:2.69050

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2,3-dichloro-1,1,1,3-tetrafluoropropane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3-dichloro-1,1,1,3-tetrafluoropropane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-dichloro-1,1,1,3-tetrafluoropropane Use and application,2,3-dichloro-1,1,1,3-tetrafluoropropane technical grade,usp/ep/jp grade.

Related News: You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. 2,3-Dichloro-1,1,1,3-tetrafluoropropane manufacturer The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 2,3-Dichloro-1,1,1,3-tetrafluoropropane supplier You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. 2,3-Dichloro-1,1,1,3-tetrafluoropropane vendor Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 2,3-Dichloro-1,1,1,3-tetrafluoropropane factory The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.